Get the Stockscreener App
40.26
3.96%
1.535
After Hours:
40.26
0.005
+0.01%
Rigel Pharmaceuticals stock is traded at $40.26, with a volume of 378.20K.
It is up +3.96% in the last 24 hours and up +34.50% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
See More
Previous Close:
$38.72
Open:
$38.8
24h Volume:
378.20K
Relative Volume:
0.99
Market Cap:
$744.80M
Revenue:
$299.77M
Net Income/Loss:
$364.23M
P/E Ratio:
2.1502
EPS:
18.7211
Net Cash Flow:
$79.27M
1W Performance:
+3.11%
1M Performance:
+34.50%
6M Performance:
-6.99%
1Y Performance:
+112.65%
1-Day Range:
$38.80
$40.33
1-Week Range:
$38.15
$40.33
52-Week Range:
$18.24
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
40.26 | 723.80M | 299.77M | 364.23M | 79.27M | 18.72 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Rigel Pharmaceuticals, Inc. Files 8-K With SEC: Corporate Details, Stock Info, and Compliance Updates - Minichart
Rigel appoints Alison L Hannah as chief medical officer - MSN
Alison Hannah joins Rigel (NASDAQ: RIGL) as new EVP and Chief Medical Officer - Stock Titan
Rigel Pharmaceuticals Appoints Dr. Alison L. Hannah as CMO (RIGL) - GuruFocus
Rigel Pharmaceuticals Appoints Alison L. Hannah as Chief Medical Officer - citybiz
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer - PR Newswire
(RIGL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
RIGL Q1 2026 Earnings: EPS Misses Estimates, Revenue Not Disclosed, Stock Edges HigherRetail Earnings Report - dars.gov.et
Rigel Pharmaceuticals, Inc.(NasdaqGS:RIGL) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Rigel Pharmaceuticals, Inc.(NasdaqGS:RIGL) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Rigel Pharmaceuticals, Inc.(NasdaqGS:RIGL) added to Russell Microcap Value Benchmark Index - marketscreener.com
Rigel Pharmaceuticals, Inc.(NasdaqGS: RIGL) added to Russell 2000 Value Benchmark - marketscreener.com
Rigel Pharmaceuticals, Inc.(NasdaqGS:RIGL) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Rigel Pharmaceuticals, Inc.(NasdaqGS:RIGL) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Rigel Pharmaceuticals, Inc.(NasdaqGS:RIGL) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Enterprise value to EBIT forward of Rigel Pharmaceuticals, Inc. – NASDAQ:RIGL - TradingView
Enterprise value to EBIT forward of Rigel Pharmaceuticals, Inc. – BX:RIGL - TradingView
Enterprise value to EBIT forward of Rigel Pharmaceuticals, Inc. – BOATS:RIGL - TradingView
RIGL Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Rigel Pharmaceuticals, Inc. – NASDAQ:RIGL - TradingView
Price to sales forward of Rigel Pharmaceuticals, Inc. – NASDAQ:RIGL - TradingView
Enterprise value to revenue forward of Rigel Pharmaceuticals, Inc. – BOATS:RIGL - TradingView
Price to earnings forward of Rigel Pharmaceuticals, Inc. – NASDAQ:RIGL - TradingView
Price to earnings forward of Rigel Pharmaceuticals, Inc. – BOATS:RIGL - TradingView
A40EFY Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Rigel Pharmaceuticals, Inc. – BOATS:RIGL - TradingView
Price to book forward of Rigel Pharmaceuticals, Inc. – NASDAQ:RIGL - TradingView
Enterprise value to EBITDA forward of Rigel Pharmaceuticals, Inc. – NASDAQ:RIGL - TradingView
Rigel Pharmaceuticals Inc (RIGL) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
RI2 Forecast — Price Target — Prediction for 2027 - TradingView
Rigel Pharmaceuticals, Inc. Actuals & Estimates (DUS:RI2) - TradingView
Rigel Pharmaceuticals (RIGL) Short Interest & Short Float | Updated Jun 2026 $RIGL - MarketBeat
Form 4 Rigel Pharmaceuticals Inc For: 24 June By Investing.com - Investing.com Nigeria
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $87,500 in stock By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $87,500 in stock - Investing.com
Rigel (RIGL) director sells 2,500 shares under 10b5-1 plan for tax withholding - Stock Titan
Rigel Pharmaceuticals Inc (RIGL) Institutional Confidence - TradingKey
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Rigel Pharmaceuticals (RIGL) CEO gets 31,700 performance-based options - Stock Titan
Rigel (RIGL) CFO’s 7,394-share performance-based stock option fully vests - Stock Titan
RIGEL (RIGL) EVP granted 7,394 fully vested performance stock options - Stock Titan
Rigel (NASDAQ: RIGL) EVP granted 7,394 fully vested performance options - Stock Titan
Form 144 RIGEL PHARMACEUTICALS INC For: 22 June By Investing.com - Investing.com South Africa
[144] RIGEL PHARMACEUTICALS INC SEC Filing - Stock Titan
Rigel Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Rigel (RIGL) CMO Lisa Rojkjaer has performance-based options fully vest - Stock Titan
RIGL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
A Look At The Transformation Around Rigel Pharmaceuticals (NASDAQ:RIGL) - Seeking Alpha
Liquidity Mapping Around (RIGL) Price Events - Stock Traders Daily
Rigel Expands Oncology Portfolio with VEPPANU Global Rights - The Globe and Mail
Rigel Pharmaceuticals Inc (RIGL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):